23,036,271
Vote Records
25,695
Companies
11,771
Funds
3,902
Managers

Home › Companies › BRIDGEBIO PHARMA INC. › 2023-2024

BRIDGEBIO PHARMA INC. 2023-2024 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 24, 2024 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Ballot items
  • 289Asset managers, any item
  • 2,630Fund votes
  • June 21, 2024Meeting date

Results at a glance

Meeting of June 21, 2024: 8 items on BRIDGEBIO PHARMA INC.’s Form 8-K, filed June 24, 2024: 3 approved · 5 passed (calculated).

Dissent

Significant dissent: 1 director (26.0% against).

Notable dissent: 1 equity or compensation plan (17.4% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore BRIDGEBIO PHARMA INC. in the interactive database Compare manager voting policies

Official 2023-2024 meeting results reported by BRIDGEBIO PHARMA INC.

These tallies are BRIDGEBIO PHARMA INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 24, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

BRIDGEBIO PHARMA INC. — official shareholder meeting results, meeting held June 21, 2024
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Eric Aguiar, M.D. 139,080,658---- 4,552,09617,266,449 97%Passed (calculated)—
Elect Director: Jennifer E. Cook 139,063,404---- 4,569,35017,266,449 97%Passed (calculated)—
Elect Director: Andrea J. Ellis 139,229,888---- 4,402,86617,266,449 97%Passed (calculated)—
Elect Director: Fred Hassan 137,076,192---- 6,556,56217,266,449 95%Passed (calculated)—
Elect Director: Ali J. Satvat 106,237,448---- 37,395,30617,266,449 74%Passed (calculated)—
2. Non-binding Advisory Vote on Compensation of Named Executive Officers 134,309,8329,254,63668,286 --17,266,449 94%Approved—
3. Ratification of Appointment of Independent Registered Accounting Firm 160,661,642196,62940,932 ---- 99.9%Approved—
4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan 118,318,37625,003,526310,852 --17,266,449 83%Approved—

Source: BRIDGEBIO PHARMA INC., Form 8-K, filed with the SEC on June 24, 2024 — read the filing on EDGAR.

How asset managers voted at the BRIDGEBIO PHARMA INC. 2023-2024 meeting

289 asset managers disclosed a vote on at least one BRIDGEBIO PHARMA INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Eric Aguiar, M.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 139,080,658WITHHELD: 4,552,096
Details: description as filed, official tally, votes by 90 asset managers

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Eric Aguiar, M.D.

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Eric Aguiar, M.D.”): 139,080,658 for, 4,552,096 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 90 asset managers below reported 37,770,710 for, 2,412,317 withheld, 303,991 abstained.

FOR
FOR: 37,770,710ABSTAIN: 303,991WITHHOLD: 2,412,317
Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,776,1170 036,680For
BlackRock3,568,9910 00For
State Street2,653,8420 0284For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco1,069,5160 00For
Charles Schwab1,052,3170 00For
AllianceBernstein00 0996,947Withhold
Lord Abbett921,3780 00For
Principal345,3880 0403,425Mixed
American Century684,2040 00For
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
MUTUAL FUND SERIES TRUST579,4140 00For
AB DISCOVERY GROWTH FUND, INC.00 0559,061Withhold
Equitable179,3760 0331,627Mixed
Capital Group413,7940 00For
Victory Capital384,5400 00For
MFS376,7560 00For
TIAA303,2780 00For
Jackson National264,3980 00For
FINANCIAL INVESTORS TRUST00 242,9950Abstain
Direxion Shares ETF Trust214,7370 00For
Hartford202,7840 00For

Showing the 25 largest of 90 asset managers. All 90 are in the interactive database (link above).

Elect Director: Ali J. Satvat

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

74% Majority: yes · of votes cast

FOR 74%WITHHELD
FOR: 106,237,448WITHHELD: 37,395,306
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Ali J. Satvat

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Ali J. Satvat”): 106,237,448 for, 37,395,306 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 74% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 23,958,343 for, 144 against, 15,167,505 withheld, 781,612 abstained.

FORWITHHOLD
FOR: 23,958,343AGAINST: 144ABSTAIN: 781,612WITHHOLD: 15,167,505
Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,723,5130 089,284For
BlackRock00 03,568,991Withhold
State Street2,7420 02,651,384Withhold
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND709,6780 0434,535Mixed
Invesco00 01,069,516Withhold
Charles Schwab1,052,3170 00For
AllianceBernstein00 0996,947Withhold
Lord Abbett00 0921,378Withhold
Principal00 0748,813Withhold
American Century00 0684,204Withhold
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
AB DISCOVERY GROWTH FUND, INC.00 0559,061Withhold
Equitable00 0511,003Withhold
Capital Group413,7940 00For
Victory Capital9940 0383,546Withhold
MFS00 0376,756Withhold
TIAA00 0303,278Withhold
Jackson National93,5510 170,8470Mixed
FINANCIAL INVESTORS TRUST00 242,9950Abstain
Direxion Shares ETF Trust00 0214,737Withhold
Hartford202,7840 00For
Bridge Builder Trust00 150,8580Abstain

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

Elect Director: Andrea J. Ellis

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 139,229,888WITHHELD: 4,402,866
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Andrea J. Ellis

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Andrea J. Ellis”): 139,229,888 for, 4,402,866 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 37,191,296 for, 2,412,317 withheld, 303,991 abstained.

FOR
FOR: 37,191,296ABSTAIN: 303,991WITHHOLD: 2,412,317
Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,776,1170 036,680For
BlackRock3,568,9910 00For
State Street2,653,8420 0284For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco1,069,5160 00For
Charles Schwab1,052,3170 00For
AllianceBernstein00 0996,947Withhold
Lord Abbett921,3780 00For
Principal345,3880 0403,425Mixed
American Century684,2040 00For
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
AB DISCOVERY GROWTH FUND, INC.00 0559,061Withhold
Equitable179,3760 0331,627Mixed
Capital Group413,7940 00For
Victory Capital384,5400 00For
MFS376,7560 00For
TIAA303,2780 00For
Jackson National264,3980 00For
FINANCIAL INVESTORS TRUST00 242,9950Abstain
Direxion Shares ETF Trust214,7370 00For
Hartford202,7840 00For
Bridge Builder Trust150,8580 00For

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

Elect Director: Fred Hassan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 137,076,192WITHHELD: 6,556,562
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Fred Hassan

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Fred Hassan”): 137,076,192 for, 6,556,562 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 36,790,951 for, 2,794,216 withheld, 322,437 abstained.

FOR
FOR: 36,790,951ABSTAIN: 322,437WITHHOLD: 2,794,216
Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,776,1170 036,680For
BlackRock3,568,9910 00For
State Street2,653,8420 0284For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco1,069,5160 00For
Charles Schwab1,052,3170 00For
AllianceBernstein00 0996,947Withhold
Lord Abbett921,3780 00For
Principal345,3880 0403,425Mixed
American Century684,2040 00For
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
AB DISCOVERY GROWTH FUND, INC.00 0559,061Withhold
Equitable179,3760 0331,627Mixed
Capital Group413,7940 00For
Victory Capital383,5460 0994For
MFS376,7560 00For
TIAA303,2780 00For
Jackson National264,3980 00For
FINANCIAL INVESTORS TRUST00 242,9950Abstain
Direxion Shares ETF Trust214,7370 00For
Hartford00 0202,784Withhold
Bridge Builder Trust150,8580 00For

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

Elect Director: Jennifer E. Cook

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 139,063,404WITHHELD: 4,569,350
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director's earlier death, resignation or removal: Jennifer E. Cook

BRIDGEBIO PHARMA INC.’s own tally for this item (“Elect Director: Jennifer E. Cook”): 139,063,404 for, 4,569,350 withheld, per its Form 8-K filed June 24, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 37,191,296 for, 2,412,317 withheld, 303,991 abstained.

FOR
FOR: 37,191,296ABSTAIN: 303,991WITHHOLD: 2,412,317
Largest asset managers voting on “To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satv” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,776,1170 036,680For
BlackRock3,568,9910 00For
State Street2,653,8420 0284For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco1,069,5160 00For
Charles Schwab1,052,3170 00For
AllianceBernstein00 0996,947Withhold
Lord Abbett921,3780 00For
Principal345,3880 0403,425Mixed
American Century684,2040 00For
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
AB DISCOVERY GROWTH FUND, INC.00 0559,061Withhold
Equitable179,3760 0331,627Mixed
Capital Group413,7940 00For
Victory Capital384,5400 00For
MFS376,7560 00For
TIAA303,2780 00For
Jackson National264,3980 00For
FINANCIAL INVESTORS TRUST00 242,9950Abstain
Direxion Shares ETF Trust214,7370 00For
Hartford202,7840 00For
Bridge Builder Trust150,8580 00For

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and…

Official resultCOMPENSATIONReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

83% Approved · of votes cast

FOR 83%AGAINST
FOR: 118,318,376AGAINST: 25,003,526
Details: description as filed, official tally, votes by 94 asset managers

Description as filed by funds: To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.

BRIDGEBIO PHARMA INC.’s own tally for this item (“4. Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan”): 118,318,376 for, 25,003,526 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 - Approval of an Amendment and Restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan The Company's stockholders approved the amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (th…”
Support: 83% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 94 asset managers below reported 33,094,009 for, 7,547,526 against, 23,210 abstained.

FORAGAINST
FOR: 33,094,009AGAINST: 7,547,526ABSTAIN: 23,210
Largest asset managers voting on “To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option a” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,812,7970 00For
BlackRock3,568,9910 00For
State Street2,650,4773,649 00For
T. Rowe Price983,540593,183 00Mixed
JANUS INVESTMENT FUND709,678434,535 00Mixed
Invesco1,069,5160 00For
Charles Schwab01,052,317 00Against
AllianceBernstein996,9470 00For
Lord Abbett0921,378 00Against
Principal403,425345,388 00Mixed
American Century0684,204 00Against
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
MUTUAL FUND SERIES TRUST579,4140 00For
AB DISCOVERY GROWTH FUND, INC.559,0610 00For
Equitable511,0030 00For
Capital Group413,7940 00For
Victory Capital0384,540 00Against
MFS0376,756 00Against
TIAA0303,278 00Against
Jackson National0264,398 00Against
FINANCIAL INVESTORS TRUST242,9950 00For
Direxion Shares ETF Trust0214,737 00Against
Hartford0202,784 00Against

Showing the 25 largest of 94 asset managers. All 94 are in the interactive database (link above).

Non-binding Advisory Vote on Compensation of Named Executive Officers

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 16 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 134,309,832AGAINST: 9,254,636

Prior year: 77.7% for (June 21, 2023 meeting) ▲ 15.9 pts

Details: description as filed, official tally, votes by 288 asset managers

Description as filed by funds: To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.

BRIDGEBIO PHARMA INC.’s own tally for this item (“2. Non-binding Advisory Vote on Compensation of Named Executive Officers”): 134,309,832 for, 9,254,636 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 90 asset managers voting on “To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,776,11736,680 00For
BlackRock3,568,9910 00For
State Street2,653,505621 00For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco01,069,516 00Against
Charles Schwab1,052,3170 00For
AllianceBernstein0996,947 00Against
Lord Abbett921,3780 00For
Principal543,013205,800 00Mixed
American Century0684,204 00Against
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
MUTUAL FUND SERIES TRUST579,4140 00For
AB DISCOVERY GROWTH FUND, INC.0559,061 00Against
Equitable179,376331,627 00Mixed
Capital Group413,7940 00For
Victory Capital383,546994 00For
MFS0376,756 00Against
TIAA303,2780 00For
Jackson National170,84793,551 00Mixed
FINANCIAL INVESTORS TRUST242,9950 00For
Direxion Shares ETF Trust214,7370 00For
Hartford0202,784 00Against

Fund voting reports, all 90 managers: 35,190,420 for, 5,167,693 against, 23,210 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 224 asset managers voting on “To cast a non-binding, advisory vote to approve the compensation of the Company's named executive officers.” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Kohlberg Kravis Roberts & Co. L.P.31,060,9710 00For
VIKING GLOBAL INVESTORS LP25,120,9910 00For
Aisling Capital Management LP6,068,1250 00For
State Street4,956,785699 00For
Laurion Capital Management LP3,450,0310 00For
BlackRock3,258,77918,660 00For
GEODE CAPITAL MANAGEMENT, LLC2,772,2350 00For
AllianceBernstein02,504,873 00Against
PICTET ASSET MANAGEMENT SA2,276,3460 00For
T. Rowe Price2,192,2610 00For
Fidelity2,129,4630 00For
Janus Henderson2,076,3400 00For
SC US (TTGP), LTD.1,860,3640 00For
HHLR ADVISORS, LTD.1,367,4890 00For
Cormorant Asset Management, LP1,317,8240 00For
Ensign Peak Advisors, Inc1,259,2130 00For
Wellington01,253,589 00Against
Capital Research Global Investors1,111,9750 00For
John Hancock1,093,3230 00For
Charles Schwab1,081,5340 00For
LORD, ABBETT & CO. LLC1,039,0490 00For
PRIMECAP MANAGEMENT CO/CA/927,2300 00For
Invesco0860,433 00Against
American Century0746,283 00Against
Octagon Capital Advisors LP690,0000 00For

Institutional-manager reports, all 224 managers: 107,930,219 for, 8,044,484 against, 18 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Ratification of Appointment of Independent Registered Accounting Firm

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 160,661,642AGAINST: 196,629

Prior year: 100.0% for (June 21, 2023 meeting) ▼ 0.1 pts

Details: description as filed, official tally, votes by 90 asset managers

Description as filed by funds: To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.

BRIDGEBIO PHARMA INC.’s own tally for this item (“3. Ratification of Appointment of Independent Registered Accounting Firm”): 160,661,642 for, 196,629 against — passed, per its Form 8-K filed June 24, 2024 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The Company's stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for the fiscal year ending December 31, 2024.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 90 asset managers below reported 40,358,053 for, 23,210 abstained.

FOR
FOR: 40,358,053ABSTAIN: 23,210
Largest asset managers voting on “To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the” at BRIDGEBIO PHARMA INC., 2023-2024
Asset managerForAgainst AbstainWithheldVote
Vanguard13,498,4990 00For
Fidelity4,812,7970 00For
BlackRock3,568,9910 00For
State Street2,654,1260 00For
T. Rowe Price1,576,7230 00For
JANUS INVESTMENT FUND1,144,2130 00For
Invesco1,069,5160 00For
Charles Schwab1,052,3170 00For
AllianceBernstein996,9470 00For
Lord Abbett921,3780 00For
Principal748,8130 00For
American Century684,2040 00For
NEW ECONOMY FUND674,1100 00For
PRIMECAP Odyssey Funds630,0300 00For
MUTUAL FUND SERIES TRUST579,4140 00For
AB DISCOVERY GROWTH FUND, INC.559,0610 00For
Equitable511,0030 00For
Capital Group413,7940 00For
Victory Capital384,5400 00For
MFS376,7560 00For
TIAA303,2780 00For
Jackson National264,3980 00For
FINANCIAL INVESTORS TRUST242,9950 00For
Direxion Shares ETF Trust214,7370 00For
Hartford202,7840 00For

Showing the 25 largest of 90 asset managers. All 90 are in the interactive database (link above).

Not shown here: this season’s fund filings also report 1 item from the meeting of June 20, 2025, which belongs to the 2024-2025 season. A meeting outside this season’s July 1 to June 30 window is not counted in this page’s items or in its totals of asset managers and fund votes.

Largest BRIDGEBIO PHARMA INC. shareholders voting in 2023-2024

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 187,122,744 shares outstanding at the time of that meeting.

Fund voting reports: top BRIDGEBIO PHARMA INC. shareholders by shares voted on “To cast a non-binding, advisory vote to approve the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1Vanguard 7.21%
2Fidelity 2.57%
3BlackRock 1.91%
4State Street 1.42%
5T. Rowe Price 0.84%
6JANUS INVESTMENT FUND 0.61%
7Invesco 0.57%
8Charles Schwab 0.56%
9AllianceBernstein 0.53%
10Lord Abbett 0.49%
Institutional-manager reports: top BRIDGEBIO PHARMA INC. shareholders by shares voted on “To cast a non-binding, advisory vote to approve the compensation of the Company's named…”, 2023-2024
#Asset manager % of shares outstanding
1Kohlberg Kravis Roberts & Co. L.P. 16.60%
2VIKING GLOBAL INVESTORS LP 13.42%
3Aisling Capital Management LP 3.24%
4State Street 2.65%
5Laurion Capital Management LP 1.84%
6BlackRock 1.75%
7GEODE CAPITAL MANAGEMENT, LLC 1.48%
8AllianceBernstein 1.34%
9PICTET ASSET MANAGEMENT SA 1.22%
10T. Rowe Price 1.17%

Reported BRIDGEBIO PHARMA INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

BRIDGEBIO PHARMA INC. holdings and ownership disclosed for the 2023-2024 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Ali J. Satvat31,476,578 16.82%Proxy statement (DEF 14A), table as of April 1, 2024
KKR Genetic Disorder L.P.31,060,971 16.60%Proxy statement (DEF 14A), table as of April 1, 2024
Viking Global Entities25,120,991 13.42%Proxy statement (DEF 14A), table as of April 1, 2024
Vanguard Group16,832,059 9.00%Form 13F, quarter ended March 31, 2024
BlackRock14,411,203 7.70%Form 13F, quarter ended March 31, 2024
Neil Kumar, Ph.D.10,114,271 5.41%Proxy statement (DEF 14A), table as of April 1, 2024
State Street5,392,862 2.88%Form 13F, quarter ended March 31, 2024
Geode Capital2,862,845 1.53%Form 13F, quarter ended March 31, 2024
Goldman Sachs2,313,759 1.24%Form 13F, quarter ended March 31, 2024
Charles Homcy, M.D.1,801,506 0.96%Proxy statement (DEF 14A), table as of April 1, 2024

Percentages above are of 187,122,744 shares outstanding, as reported by BRIDGEBIO PHARMA INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At BRIDGEBIO PHARMA INC.'s shareholder meeting held June 21, 2024, in the 2023-2024 proxy season, 289 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 2,630 separate fund positions. On the most widely held item on that ballot — To cast a non-binding, advisory vote to approve the compensation of the Company's named… — BRIDGEBIO PHARMA INC.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: BRIDGEBIO PHARMA INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 24, 2024.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BRIDGEBIO PHARMA INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

BRIDGEBIO PHARMA INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.

Cite this page

Proxy Votes Now, “BRIDGEBIO PHARMA (BBIO) 2024 Annual Meeting: Shareholder Vote Results”, https://proxyvotesnow.com/company/bridgebio-pharma-inc/2024 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.